CSIMarket
 


Aldeyra Therapeutics Inc   (ALDX)
Other Ticker:  
 

Aldeyra Therapeutics Inc 's Total Debt to Equity

ALDX's quarterly Total Debt to Equity and Total Debt, Equity growth


Due to net new borrowings of 0.6%, Total Debt to Equity fell to 0.13, above the Aldeyra Therapeutics Inc 's average Total Debt to Equity.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 6 other companies have achieved lower Total Debt to Equity than Aldeyra Therapeutics Inc in the III Quarter 2023. While Total Debt to Equity total ranking has improved so far in the third quarter 2023 to 164, from total ranking in the second quarter 2023 at 307 .

Explain Debt to Equity Ratio?
What is the structure of ALDX´s Total Debt?
How valuable is the ALDX´s Equity?


ALDX Total Debt to Equity (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -24.16 % -25.37 % -28.03 % -26.6 % -26.16 %
Y / Y Total Debt Change 2.32 % 2.25 % 2.15 % 2.14 % 2.15 %
Total Debt to Equity MRQ 0.13 0.12 0.12 0.1 0.1
ALDX's Total Ranking # 164 # 307 # 148 # 452 # 469
Seq. Equity Change -5.29 % -5.36 % -9.12 % -6.9 % -6.8 %
Seq. Total Debt Change 0.6 % 0.63 % 0.55 % 0.53 % 0.53 %



Total Debt to Equity third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 7
Healthcare Sector # 17
Overall Market # 164


Total Debt to Equity Statistics
High Average Low
0.34 0.11 0.03
(Mar 31 2020)   (Sep 30 2017)




Financial Statements
Aldeyra Therapeutics Inc 's Equity $ 123 Millions Visit ALDX's Balance sheet
Aldeyra Therapeutics Inc 's Total Debt $ 16 Millions Visit ALDX's Balance sheet
Source of ALDX's Sales Visit ALDX's Sales by Geography


Cumulative Aldeyra Therapeutics Inc 's Total Debt to Equity

ALDX's Total Debt to Equity for the trailling 12 Months

ALDX Total Debt to Equity

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -24.16 % -25.37 % -28.03 % -26.6 % -26.16 %
Y / Y Total Debt TTM Growth 2.32 % 2.25 % 2.15 % 2.14 % 2.15 %
Total Debt to Equity TTM 0.12 0.11 0.1 0.09 0.09
Total Ranking TTM # 593 # 36 # 27 # 36 # 826
Seq. Equity TTM Growth -5.29 % -5.36 % -9.12 % -6.9 % -6.8 %
Seq. Total Debt TTM Growth 0.6 % 0.63 % 0.55 % 0.53 % 0.53 %


On the trailing twelve months basis Due to the net new borrowings of 0.6% during the trailing twelve months finishing in the III Quarter 2023, cumulativeTotal Debt to Equity improved to 0.12, above the Aldeyra Therapeutics Inc 's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 60, during the past 12 months, other companies have achieved lower Total Debt to Equity than Aldeyra Therapeutics Inc . While Total Debt to Equity total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 36 to 593.

Explain Debt to Equity Ratio?
What is the structure of ALDX´s Total Debt?
How valuable is the ALDX´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 61
Healthcare Sector # 138
Within the Market # 593


trailing twelve months Total Debt to Equity Statistics
High Average Low
0.3 0.11 0.01
(Jun 30 2020)   (Jun 30 2019)




Companies with similar Total Debt to Equity in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Total Debt to EquitySep 30 2023 MRQ Total DebtSep 30 2023 MRQ Equity
Werewolf Therapeutics Inc   0.35 $ 39.231  Millions$ 112.443  Millions
Eton Pharmaceuticals Inc   0.34 $ 5.737  Millions$ 16.892  Millions
Roivant Sciences Ltd   0.33 $ 438.443  Millions$ 1,325.633  Millions
Earth Science Tech Inc   0.31 $ 0.599  Millions$ 1.934  Millions
Centessa Pharmaceuticals Plc  0.29 $ 74.000  Millions$ 259.390  Millions
Abvc Biopharma Inc   0.28 $ 2.507  Millions$ 9.062  Millions
Hcw Biologics Inc   0.27 $ 6.333  Millions$ 23.867  Millions
Kineta Inc   0.26 $ 0.765  Millions$ 2.889  Millions
Organogenesis Holdings Inc   0.24 $ 67.600  Millions$ 276.865  Millions
Legend Biotech Corporation  0.22 $ 281.384  Millions$ 1,251.371  Millions
Biomarin Pharmaceutical Inc  0.22 $ 1,085.984  Millions$ 4,896.897  Millions
Alkermes Plc   0.21 $ 291.366  Millions$ 1,355.583  Millions
Cue Biopharma Inc   0.21 $ 9.123  Millions$ 42.666  Millions
Innovation Pharmaceuticals Inc   0.20 $ 0.238  Millions$ 1.162  Millions
Vera Therapeutics Inc   0.20 $ 25.042  Millions$ 123.707  Millions
Assertio Holdings inc   0.20 $ 38.866  Millions$ 192.873  Millions
Inozyme Pharma Inc   0.20 $ 32.065  Millions$ 160.213  Millions
Sanofi  0.19 $ 16,068.640  Millions$ 83,275.360  Millions
Avadel Pharmaceuticals Plc  0.19 $ 21.187  Millions$ 110.149  Millions
Actinium Pharmaceuticals Inc   0.19 $ 8.150  Millions$ 43.583  Millions
Novabay Pharmaceuticals Inc   0.18 $ 1.270  Millions$ 7.037  Millions
Savara Inc   0.18 $ 26.281  Millions$ 146.544  Millions
Geron Corp  0.18 $ 51.898  Millions$ 290.614  Millions
Opko Health Inc   0.17 $ 243.403  Millions$ 1,444.568  Millions
Oncotelic Therapeutics Inc   0.15 $ 1.832  Millions$ 12.086  Millions
Gossamer Bio Inc   0.15 $ 15.247  Millions$ 104.617  Millions
Ardelyx Inc   0.14 $ 27.229  Millions$ 191.161  Millions
Beigene ltd   0.14 $ 531.051  Millions$ 3,763.234  Millions
Kamada Ltd   0.14 $ 34.379  Millions$ 244.021  Millions
United Therapeutics Corporation  0.14 $ 800.000  Millions$ 5,712.100  Millions

Date modified: 2023-11-04T19:52:30+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com